Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients.

Junichiro YudaChristine WillDarren C PhillipsLinu AbrahamCory AlveyAbraham AvigdorWayne R BuckLauren BesenhoferErwin BoghaertDong ChengDan CojocariKelly DoyleT Matthew HansenKevin HuangEric F JohnsonAndrew S JuddRussell A JudgeJohn C KalvassAaron KunzerLloyd T LamRachel LiRuth L MartinAnthony MastracchioMike MittenAdam PetrichJin WangJames E WardHaichao ZhangXilu WangJohannes E WolffKatherine M Bell-McGuinnAndrew J Souers

Published in: Communications medicine (2023)

The selectivity of ABBV-467 suggests that treatment-induced troponin release is a consequence of MCL-1 inhibition and therefore may represent a class effect of MCL-1 inhibitors in human patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
peritoneal dialysis
high glucose
pluripotent stem cells